Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Basel Medical Group Ltd ( (BMGL) ) just unveiled an announcement.
On January 23, 2026, Basel Medical Group Ltd announced it had received a delinquency notification from Nasdaq after its shares traded below the minimum required bid price of $1 for 30 consecutive business days, placing the company out of compliance with the exchange’s listing standards. Basel now has an initial 180-day grace period, through July 21, 2026, to regain compliance—potentially via a higher sustained share price or a reverse stock split—and could receive an additional 180 days if it meets other Nasdaq listing criteria, while trading in its shares on Nasdaq remains unaffected as the company works with advisers on a rectification plan, a development that underscores near-term listing risk for shareholders but does not immediately disrupt operations.
More about Basel Medical Group Ltd
Basel Medical Group Ltd is a Singapore-based private healthcare provider specializing in orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, neurosurgical treatments, executive health screening, occupational medicine, rehabilitation, mental and women’s health and general practice. Operating through clinics across multiple locations in Singapore, the group has built a more than 20-year track record and strong corporate client relationships, particularly in the construction, marine and oil & gas sectors, positioning it to benefit from growing private healthcare demand in Singapore and Southeast Asia.
Average Trading Volume: 84,008
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.27M
For detailed information about BMGL stock, go to TipRanks’ Stock Analysis page.